 |
 |
Dear all, I have received an email from Doris-Ann Williams at BIVDA who says that UK diagnostics manufacturers are experiencing a crisis due to the problems associated with obtaining clinical samples for assay validation, QC of kit batches etc in the aftermath of the 'Alder Hey' report in the UK (retention of organs/tissues). Many of you, like my own hospital, will be taking steps to obtain (at least passive) consent for use of samples within the hospital for QC, research etc by displaying appropriately worded notices in venepuncture areas etc, but we are still very nervous about releasing samples outside the Trust, especially in exchange for payment, however that payment is described. However, it is clearly having an impact on industry. If anyone has established procedures for release of samples to outside agencies in this way, Doris-Ann would be very pleased to hear from you ([log in to unmask]) and will act as a clearing house to put you in touch with companies who need material. If anyone has any comments on the problem and/or possible solutions, it would be interesting to read them on the mailbase. If people think it would be valuable, I'm sure the ACB could host discussions between the profession (ACB/RCPath) and the industry to establish some sort of code of practice. Mike Hallworth ACB Chairman ------ACB discussion List Information-------- This is an open discussion list for the academic and clinical community working in clinical biochemistry. Please note, archived messages are public and can be viewed via the internet. Views expressed are those of the individual and they are responsible for all message content. ACB Web Site http://www.acb.org.uk List Archives http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html List Instructions (How to leave etc.) http://www.jiscmail.ac.uk/